Athira Pharma, Inc.

1. Represents shares of common stock sold to cover tax withholding and remittance obligations in connection with the vesting of restricted stock units ("RSU") pursuant to mandatory "sell to cover" policies maintained by the Issuer and provisions contained in the reporting person's applicable RSU agreement, and does not represent a discretionary sale by the reporting person. No additional shares of common stock were sold by the reporting person.

2. The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $5.03 to $5.70, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.

3. Reflects Common Stock held by Irrevocable Trust of OSL held for the benefit of Dr. Litton's children.

4. Reflects Common Stock held by Irrevocable Trust of SWL held for the benefit of Dr. Litton's children.

5. Reflects Common Stock held by Irrevocable Trust of WGL held for the benefit of Dr. Litton's children.

6. Each RSU represents a contingent right to receive one (1) share of Issuer's common stock.

7. On March 3, 2025, the reporting person was granted 22,254 RSUs (as adjusted for the 10-for-1 reverse stock split completed on September 17, 2025). 100% of the RSUs vested on the one (1) year anniversary of the grant date.